Pfizer Korea's counter attacks for Norvasc defence.

Published: 2004-11-18 06:58:00

Updated: 2004-11-18 06:58:00

Pfizer Korea began to counter attack against the Norvasc rival products by quoting their survey data describing a superior product position to other rivals in terms of its efficacy and safety proven for a long time.

Recently the pharmaceutical industries and wholesalers showed a movement of s...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK